Auristatin class antibody drug conjugates: Research advances / 国际药学研究杂志

ABSTRACT

Antibody drug conjugates (ADC) are a novel biological targeted anti-cancer agents that have the specificity target of monoclonal antibody and the significant cytotoxicity of the drug. It can not only improve the curative effect of the antibody but also expand the scope of clinical application of the small molecule toxins. Auristatins have been widely used in ADC and has achieved great success because of their powerful biological activity. The structure feature of auristatins is different from that of other cytotoxins-which determine the design of this kind of ADC′ linker is different from others′. We review the progress in each component and the latest clinical research of the auristatin class ADC- which may benefit to the further development of ADC.